Skip to content

The ophthalmic phacoemulsification surgical system is used in prospective, multicenter, randomized controlled trials of cataract phacoemulsification

The ophthalmic phacoemulsification surgical system is used in prospective, multicenter, randomized controlled trials of cataract phacoemulsification

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065001
Enrollment
Unknown
Registered
2022-10-25
Start date
2022-10-26
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

It is suitable for cataract surgery, lens emulsification, perfusion and suction, anterior segment vitrectomy and coagulation of bleeding points during operation.

Interventions

Test group:Ophthalmic phacoemulsification system produced by Innolcon Medical
Control group:Centurion equipment (Alcon)

Sponsors

Ophthalmology Hospital Affiliated to Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age: 50-75, regardless of gender; 2. Slit lamp examination showed that one eye or both eyes had cataract, and phacoemulsification combined with intraocular lens implantation was planned for one eye; 3. The best corrected visual acuity of the affected eye was<0.5; 4. The hardness of the lens nucleus of the operative eye was classified as Grade II-IV by Emery; 5. Good compliance, able to follow up according to the test process, voluntarily participate in the study, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. There is eye inflammation that seriously affects vision (such as acute and chronic dacryocystitis, dacryocystitis, infection, etc.); 2. There are other eye diseases that seriously affect vision (such as retinopathy, glaucoma, etc.); 3. Lens dislocation; 4. Predicted retinal visual acuity<0.3; 5. The density of corneal endothelial cells was less than 1500 cells/mm2; 6. The patient has a history of intraocular surgery within 2 years or ocular trauma within 3 months; 7. Suffering from serious systemic disease and not suitable for surgery; 8. Suffering from mental illness, cognitive dysfunction leads to poor compliance; 9. Pregnant or lactating women; 10. The researcher thinks it is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity (BCVA);

Secondary

MeasureTime frame
Corneal endothelial cell loss;Corneal edema;Naked eye vision;Accumulated energy consumption;Aspiration Time;Ultrasonic time;Estimated Fluid Used;Instrument durability evaluation;Satisfaction evaluation of the researcher on the test instrument;

Countries

China

Contacts

Public ContactYu Ayong

Ophthalmology Hospital Affiliated to Wenzhou Medical University

yaybetter@hotmail.com+86 13868760001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026